OmniActive’s Muvz Clinically Proven to Support Joint & Mobility Health

OmniActive Health Technologies , a leading global supplier of ingredient solutions for the nutrition, health, and wellness industries, announces a peer-reviewed clinical study confirming the benefits of Muvz for joint and mobility support. Published in Drug Design, Development and Therapy, the randomized, placebo-controlled study involved 157 adults (40-60 years) over three months.

Key findings:

• Significant improvement in musculoskeletal health scores by day 30
• Enhanced joint & low-back comfort, reducing post-activity discomfort
• Improved flexibility & range of motion by day 90

Muvz, a blend of Vitex negundo and Zingiber officinale, is known for its anti-inflammatory & analgesic properties. Following OmniActive’s acquisition of ENovate Biolife, Muvz strengthens its position as a natural mobility solution for active adults.

23-03-2025

• Pharma GMP
• Food GMP
• Clinical Research
• Medical Device
• Environmental Health and Safety
• Healthcare
• Nutrition